HT JOINS EU CONSORTIUM LIFETIME
Human Technopole is now an Associate Partner of LifeTime, the pan-European research initiative that aims to revolutionise healthcare by tracking and understanding human diseases at single cell resolution to transform patients’ care and the sustainability of healthcare systems.
Joining the LifeTime community is an important opportunity for Human Technopole to build a strategic network of relevant European partners that share our ambition and goals.
Human Technopole’s mission is fully aligned with LifeTime’s overarching aim to tackle complex human diseases. Specifically, the three defining pillars of LifeTime (single-cell multiomics, organoids and machine learning-based deconvolution) are represented in HT by the close integration of Centres and Core Facilities featuring leading expertise in these fields.
Together with the University of Milan, the European Institute of Oncology (IEO) and the Sacco Hospital, Human Technopole is already part of the Italian branch of the initiative Lifetime for COVID19, which for the upcoming two years will be led by the Head of our Research Centre for Neurogenomics, Prof. Giuseppe Testa.
The LifeTime consortium gathers over 120 leading scientists from over 90 European research institutes. The University of Milan is the Italian partner of the consortium and other Italian associate partners include the European Institute of Oncology, Fondazione Istituto FIRC di Oncologia Molecolare, the Institute for Biomedical Technologies and the Institute of Photonics and Nanotechnologies of the Italian National Research Council as well as many prominent Italian universities.
Share:
You could also like:
-
Colorectal Cancer: ML Enhances Cetuximab Response Predictions
An international collaborative study led by Human Technopole, Candiolo Cancer Institute IRCCS in Turin, the University of Turin, and the Wellcome Sanger Institute in Cambridge (UK) has identified new factors associated with therapeutic response in colorectal cancer. The research has led to the development of a machine-learning model capable of accurately predicting the effects of cetuximab, a drug in clinical use, on different colorectal tumour subtypes. Funded by the AIRC Foundation, the study paves the way to identifying molecular features that could serve as biomarkers for predicting treatment response in patients with this type of cancer.
-
Human Technopole Foundation’s Supplier List online
The Human Technopole Foundation’s Supplier Register is now online.
-
HT Director Zerial Awarded Mercurio Prize for Excellence in Research
The Human Technopole Director, Marino Zerial, has been awarded the 2024 Mercurio Prize in the “Research and Development” category, in recognition of the excellence of his research in the field of cell biology. Zerial, renowned for his studies on the mechanisms of endocytosis and cellular transport, has made significant contributions to the understanding of cellular dynamics, with potential therapeutic applications for diseases such as liver conditions.
-
A new model system for cortical development in vitro
Researchers from Human Technopole, the Institute of Molecular Biotechnology and Bicocca University established a method for developing brain assembloids that allows reproducing salient aspects of the antero-posterior polarity of the human cerebral cortex in vitro and opens new possibilities for disease modelling. The study is published in Nature Methods.
-
The National Facility for Genomics with Clelia Peano
Meet Clelia Peano, Head of the National Facility for Genomics. The Facility offers cutting-edge services to develop robust experimental and analytical workflows to explore different genomic research areas, including DNA and RNA analysis, chromatin structure, and epigenetic mechanisms regulating transcription. The goal is to enhance genomic research in all its aspects, benefiting the entire Italian scientific community.